Does the media prefer OGN or PCRX?

In the previous week, Organon & Co. had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 2 mentions for Organon & Co. and 1 mentions for Pacira BioSciences. Organon & Co.'s average media sentiment score of 0.51 beat Pacira BioSciences' score of 0.00 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TARS or PCRX?

In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Pacira BioSciences. MarketBeat recorded 6 mentions for Tarsus Pharmaceuticals and 1 mentions for Pacira BioSciences. Tarsus Pharmaceuticals' average media sentiment score of 0.68 beat Pacira BioSciences' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ARQT or PCRX?

In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than Pacira BioSciences. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 1 mentions for Pacira BioSciences. Arcutis Biotherapeutics' average media sentiment score of 0.47 beat Pacira BioSciences' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MOR or PCRX?

Pacira BioSciences has a consensus price target of $29.83, indicating a potential upside of 20.83%. Given Pacira BioSciences' stronger consensus rating and higher probable upside, analysts clearly believe Pacira BioSciences is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pacira BioSciences 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable valuation and earnings, MOR or PCRX?

Pacira BioSciences has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Pacira BioSciences $726.41M 1.35 $7.03M $0.35 70.54

Does the media favor PCRX or MBX?

In the previous week, MBX Biosciences had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 3 mentions for MBX Biosciences and 1 mentions for Pacira BioSciences. MBX Biosciences' average media sentiment score of 0.45 beat Pacira BioSciences' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pacira BioSciences (PCRX) Competitors

$24.69 +0.21 (+0.86%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$24.54 -0.16 (-0.63%)

As of 09/18/2026 07:30 PM Eastern

Compare

PCRX vs. OGN, TARS, ARQT, MOR, and MBX

Should you buy Pacira BioSciences stock or one of its competitors? Pacira BioSciences's main competitors and comparable companies include Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), Arcutis Biotherapeutics (ARQT), MorphoSys (MOR), and MBX Biosciences (MBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Pacira BioSciences compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Pacira BioSciences (NASDAQ:PCRX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Organon & Co. has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Organon & Co. has a net margin of 3.41% compared to Pacira BioSciences' net margin of 1.96%. Organon & Co.'s return on equity of 88.97% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Pacira BioSciences	1.96%	9.68%	5.30%

Organon & Co. has higher revenue and earnings than Pacira BioSciences. Organon & Co. is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.77
Pacira BioSciences	$726.41M	1.35	$7.03M	$0.35	70.54

In the previous week, Organon & Co. had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 2 mentions for Organon & Co. and 1 mentions for Pacira BioSciences. Organon & Co.'s average media sentiment score of 0.51 beat Pacira BioSciences' score of 0.00 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organon & Co. presently has a consensus price target of $11.40, suggesting a potential downside of 16.70%. Pacira BioSciences has a consensus price target of $29.83, suggesting a potential upside of 20.83%. Given Pacira BioSciences' stronger consensus rating and higher possible upside, analysts plainly believe Pacira BioSciences is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Pacira BioSciences	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Organon & Co. beats Pacira BioSciences on 9 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Pacira BioSciences (NASDAQ:PCRX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Tarsus Pharmaceuticals currently has a consensus price target of $94.00, suggesting a potential upside of 20.37%. Pacira BioSciences has a consensus price target of $29.83, suggesting a potential upside of 20.83%. Given Pacira BioSciences' higher probable upside, analysts plainly believe Pacira BioSciences is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
Pacira BioSciences	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Pacira BioSciences has a net margin of 1.96% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Pacira BioSciences' return on equity of 9.68% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Pacira BioSciences	1.96%	9.68%	5.30%

Pacira BioSciences has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	7.59	-$66.42M	-$1.09	N/A
Pacira BioSciences	$726.41M	1.35	$7.03M	$0.35	70.54

Tarsus Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Pacira BioSciences. MarketBeat recorded 6 mentions for Tarsus Pharmaceuticals and 1 mentions for Pacira BioSciences. Tarsus Pharmaceuticals' average media sentiment score of 0.68 beat Pacira BioSciences' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Pacira BioSciences beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Pacira BioSciences compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Pacira BioSciences (NASDAQ:PCRX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than Pacira BioSciences. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 1 mentions for Pacira BioSciences. Arcutis Biotherapeutics' average media sentiment score of 0.47 beat Pacira BioSciences' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Pacira BioSciences has higher revenue and earnings than Arcutis Biotherapeutics. Pacira BioSciences is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.47	-$16.14M	$0.21	120.69
Pacira BioSciences	$726.41M	1.35	$7.03M	$0.35	70.54

99.7% of Pacira BioSciences shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Arcutis Biotherapeutics presently has a consensus target price of $35.57, indicating a potential upside of 40.35%. Pacira BioSciences has a consensus target price of $29.83, indicating a potential upside of 20.83%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pacira BioSciences	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Arcutis Biotherapeutics has a net margin of 6.15% compared to Pacira BioSciences' net margin of 1.96%. Arcutis Biotherapeutics' return on equity of 15.05% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Pacira BioSciences	1.96%	9.68%	5.30%

Summary

Arcutis Biotherapeutics beats Pacira BioSciences on 12 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Pacira BioSciences (NASDAQ:PCRX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Pacira BioSciences has a net margin of 1.96% compared to MorphoSys' net margin of -226.79%. Pacira BioSciences' return on equity of 9.68% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Pacira BioSciences	1.96%	9.68%	5.30%

In the previous week, Pacira BioSciences had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Pacira BioSciences and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 equaled Pacira BioSciences'average media sentiment score.

Company	Overall Sentiment
MorphoSys	Neutral
Pacira BioSciences	Neutral

Pacira BioSciences has a consensus price target of $29.83, indicating a potential upside of 20.83%. Given Pacira BioSciences' stronger consensus rating and higher probable upside, analysts clearly believe Pacira BioSciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pacira BioSciences	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Pacira BioSciences has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Pacira BioSciences	$726.41M	1.35	$7.03M	$0.35	70.54

Summary

Pacira BioSciences beats MorphoSys on 13 of the 15 factors compared between the two stocks.

How does Pacira BioSciences compare to MBX Biosciences?

Pacira BioSciences (NASDAQ:PCRX) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Pacira BioSciences has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market.

Pacira BioSciences currently has a consensus target price of $29.83, suggesting a potential upside of 20.83%. MBX Biosciences has a consensus target price of $77.00, suggesting a potential upside of 22.40%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Pacira BioSciences has a net margin of 1.96% compared to MBX Biosciences' net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	1.96%	9.68%	5.30%
MBX Biosciences	N/A	-26.02%	-24.94%

99.7% of Pacira BioSciences shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, MBX Biosciences had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 3 mentions for MBX Biosciences and 1 mentions for Pacira BioSciences. MBX Biosciences' average media sentiment score of 0.45 beat Pacira BioSciences' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pacira BioSciences has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.35	$7.03M	$0.35	70.54
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Summary

Pacira BioSciences beats MBX Biosciences on 9 of the 16 factors compared between the two stocks.

Get Pacira BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCRX vs. The Competition

Export

Metric	Pacira BioSciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$984.19M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	70.54	797.25	275.49	25.40
Price / Sales	1.35	753.62	646.01	89.45
Price / Cash	6.40	86.36	76.25	51.42
Price / Book	1.53	10.53	10.46	6.33
Net Income	$7.03M	$2.82B	$3.49B	$358.33M
7 Day Performance	-2.64%	1.69%	0.59%	1.12%
1 Month Performance	3.61%	0.24%	-1.74%	-2.39%
1 Year Performance	-7.39%	3.95%	18.13%	5.35%

Pacira BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCRX Pacira BioSciences	2.7512 of 5 stars	$24.69 +0.9%	$29.83 +20.8%	-7.4%	$984.19M	$726.41M	70.54	829	Analyst Downgrade
OGN Organon & Co.	1.252 of 5 stars	$13.65 +0.0%	$11.40 -16.5%	+30.8%	$3.58B	$6.13B	17.72	10,000
TARS Tarsus Pharmaceuticals	3.0717 of 5 stars	$79.95 +0.8%	$92.57 +15.8%	+42.0%	$3.48B	$606.33M	N/A	50	Analyst Upgrade Insider Trade
ARQT Arcutis Biotherapeutics	3.7891 of 5 stars	$24.27 +1.6%	$35.57 +46.6%	+45.8%	$3.00B	$463.98M	115.58	354	News Coverage Positive News Gap Up
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCRX) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacira BioSciences (PCRX) Competitors

PCRX vs. OGN, TARS, ARQT, MOR, and MBX

How does Pacira BioSciences compare to Organon & Co.?

Summary

How does Pacira BioSciences compare to Tarsus Pharmaceuticals?

Summary

How does Pacira BioSciences compare to Arcutis Biotherapeutics?

Summary

How does Pacira BioSciences compare to MorphoSys?

Summary

How does Pacira BioSciences compare to MBX Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacira BioSciences (PCRX) Competitors

PCRX vs. OGN, TARS, ARQT, MOR, and MBX

How does Pacira BioSciences compare to Organon & Co.?

Do insiders & institutionals hold more shares of OGN or PCRX?

Which has more volatility & risk, OGN or PCRX?

Is OGN or PCRX more profitable?

Which has preferable valuation and earnings, OGN or PCRX?

Does the media prefer OGN or PCRX?

Do analysts prefer OGN or PCRX?

Summary

How does Pacira BioSciences compare to Tarsus Pharmaceuticals?

Do analysts prefer TARS or PCRX?

Is TARS or PCRX more profitable?

Which has better earnings and valuation, TARS or PCRX?

Which has more risk & volatility, TARS or PCRX?

Does the media prefer TARS or PCRX?

Do institutionals & insiders hold more shares of TARS or PCRX?

Summary

How does Pacira BioSciences compare to Arcutis Biotherapeutics?

Does the media prefer ARQT or PCRX?

Which has more risk and volatility, ARQT or PCRX?

Which has preferable earnings & valuation, ARQT or PCRX?

Do institutionals & insiders believe in ARQT or PCRX?

Do analysts recommend ARQT or PCRX?

Is ARQT or PCRX more profitable?

Summary

How does Pacira BioSciences compare to MorphoSys?

Which has more risk & volatility, MOR or PCRX?

Do insiders and institutionals have more ownership in MOR or PCRX?

Is MOR or PCRX more profitable?

Does the media refer more to MOR or PCRX?

Do analysts recommend MOR or PCRX?

Which has preferable valuation and earnings, MOR or PCRX?

Summary

How does Pacira BioSciences compare to MBX Biosciences?

Which has more volatility & risk, PCRX or MBX?

Do analysts prefer PCRX or MBX?

Is PCRX or MBX more profitable?

Do institutionals & insiders hold more shares of PCRX or MBX?

Does the media favor PCRX or MBX?

Which has higher valuation & earnings, PCRX or MBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools